Literature DB >> 9042431

Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes.

M J Maeurer1, W Walter, D Martin, L Zitvogel, E Elder, W Storkus, M T Lotze.   

Abstract

Despite increasing survival rates for patients with colorectal cancer, additional treatment options are required, including active or passive immunotherapy for patients with metastatic disease. Freshly harvested colorectal cancer specimens and in vitro cultured colorectal cancer cell lines were examined for IL-7 protein secretion in order to examine the potential role of this cytokine in the interaction between tumour cells and the host immune system. Freshly harvested colorectal cancer specimens (21/21), or normal adjacent mucosa (3/3), as well as long-term established colorectal cancer cell lines (3/4) exhibited IL-7 mRNA expression as detected by RT-PCR and confirmed by Southern Blot analysis. Freshly harvested colorectal cancer tissue (16/18), or long-term established colorectal cancer cell lines (2/4) secreted in vitro IL-7 as detected by ELISA. In contrast, breast, pancreatic, or lung cancer cell lines, as well as several haematopoietic cancer cells lines, tested negative for IL-7 mRNA and protein. The authors tested different cytokines (IL-1 beta, IL-2, IL-7, or a combination of IL-1 beta/IL-7) in vitro for the ability to expand tumour-infiltrating T lymphocytes (TIL) from individual patients (n = 9) with colorectal cancer. TIL populations were tested at day 14 after in vitro propagation for phenotypic analysis by FACS and for reactivity directed against NK and LAK sensitive target cells and autologous cancer cells as measured by cytotoxicity and cytokine release. TIL obtained from colorectal cancer lesions can be efficiently expanded in the presence of IL-7, some(3/9) of which appear to exhibit autologous tumour recognition as measured by cytolytic effector functions and by detection of IFN gamma and TNF alpha release. Detection of IL-7 mRNA expression in colorectal cancer, in normal mucosa adjacent to tumour, as well as the ability of colorectal cancer tissue to secrete IL-7, raises new questions about the biology of the host/tumour interactions in colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9042431     DOI: 10.1046/j.1365-3083.1997.d01-384.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  26 in total

1.  IL-7 splicing variant IL-7δ5 induces EMT and metastasis of human breast cancer cell lines MCF-7 and BT-20 through activation of PI3K/Akt pathway.

Authors:  Jie Yang; Zhi Zeng; Yuyu Peng; Jianhua Chen; Ling Pan; Deshun Pan
Journal:  Histochem Cell Biol       Date:  2014-04-26       Impact factor: 4.304

2.  Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics.

Authors:  Jaime A Espinoza; Shakila Jabeen; Richa Batra; Elena Papaleo; Vilde Haakensen; Vera Timmermans Wielenga; Maj-Lis Møller Talman; Nils Brunner; Anne-Lise Børresen-Dale; Pavel Gromov; Åslaug Helland; Vessela N Kristensen; Irina Gromova
Journal:  Oncoimmunology       Date:  2016-10-24       Impact factor: 8.110

3.  Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients.

Authors:  Nikolaos Tsavaris; Ioannis F Voutsas; Christos Kosmas; Angelos D Gritzapis; Constantin N Baxevanis
Journal:  Invest New Drugs       Date:  2010-09-07       Impact factor: 3.850

4.  Antigen-driven T-cell selection in patients with cervical cancer as evidenced by T-cell receptor analysis and recognition of autologous tumor.

Authors:  H Pilch; H Höhn; C Neukirch; K Freitag; P G Knapstein; B Tanner; M J Maeurer
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

5.  Ex vivo expansion of memory CD8 T cells from lymph nodes or spleen through in vitro culture with interleukin-7.

Authors:  Christina Kittipatarin; Annette R Khaled
Journal:  J Immunol Methods       Date:  2009-03-17       Impact factor: 2.303

6.  Can immunotherapy by gene transfer tip the balance against colorectal cancer?

Authors:  S M Todryk; H Chong; R G Vile; H Pandha; N R Lemoine
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

Review 7.  Common gamma chain cytokines in combinatorial immune strategies against cancer.

Authors:  Stephanie R Pulliam; Roman V Uzhachenko; Samuel E Adunyah; Anil Shanker
Journal:  Immunol Lett       Date:  2015-11-17       Impact factor: 3.685

8.  New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models.

Authors:  Julie A Hixon; Caroline Andrews; Lila Kashi; Casey L Kohnhorst; Emilee Senkevitch; Kelli Czarra; Joao T Barata; Wenqing Li; Joel P Schneider; Scott T R Walsh; Scott K Durum
Journal:  Leukemia       Date:  2019-08-22       Impact factor: 11.528

Review 9.  Flip the coin: IL-7 and IL-7R in health and disease.

Authors:  João T Barata; Scott K Durum; Benedict Seddon
Journal:  Nat Immunol       Date:  2019-11-19       Impact factor: 25.606

10.  Interleukin (IL)-7 Signaling in the Tumor Microenvironment.

Authors:  Iwona Bednarz-Misa; Mariusz A Bromke; Małgorzata Krzystek-Korpacka
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.